title: Anti-DFS70 antibodies in 597 healthy hospital workers.
abstract: OBJECTIVE
  Autoantibodies against DFS70 (dense fine speckles 70) antigen (also known as lens epithelium-derived growth factor) have been recently identified among the antinuclear antibodies (ANAs) in patients with atopic disorders. We undertook this study to examine the frequency of anti-DFS70 antibodies in a large number of healthy people.
  
  
  METHODS
  Sera of 597 healthy individuals working in a hospital (142 men, 455 women) were analyzed for ANAs and for anti-DFS70 antibodies by indirect immunofluorescence (IIF) with HEp-2 cells as a substrate and by immunoblotting using DFS70 recombinant protein and whole HeLa cell extract.
  
  
  RESULTS
  ANAs were present in 20% of all individuals by IIF. Nine percent of subjects were ANA positive at a serum dilution of 1:40, 4.0% at 1:80, 5.5% at 1:160, 1.0% at 1:320, and 0.3% at 1:640. There were 64 anti-DFS70 antibody-positive individuals. Surprisingly, this was 11% of the whole population and 54% of the ANA-positive population. The percentage of female anti-DFS70 antibody-positive subjects (86%; 55 of 64 subjects) was higher than the percentage of female anti-DFS70 antibody-negative subjects (75%; 398 of 533 subjects) (P < 0.05). The prevalence of anti-DFS70 antibody-positive sera decreased with increasing age (P = 0.0017).
  
  
  CONCLUSIONS
  Considering that anti-DFS70 antibody positivity is rare in patients with systemic autoimmune diseases, introducing the anti-DFS70 antibody examination as a screening test for ANA-positive persons could be used to rule out systemic autoimmune diseases, resulting in considerable cost-saving potential. In addition, this test defines a subpopulation of healthy people in whom long-term followup might reveal health-related implications of this finding, since anti-DFS70 antibodies have been shown to be associated with some illnesses.
authors.affiliation: Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Watanabe
authors.forename: Masanari
authors.initials: M
authors.lastname: Kodera
authors.forename: Kazumitsu
authors.initials: K
authors.lastname: Sugiura
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Usuda
authors.forename: Eng M
authors.initials: EM
authors.lastname: Tan
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Takasaki
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tomita
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Muro
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis*; D001323:Autoantibodies / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006367:HeLa Cells; D006282:Health Personnel; D006304:Health Status; D006761:Hospitals; D006801:Humans; D015151:Immunoblotting; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012216:Rheumatic Diseases / Q000276:immunology; D011795:Surveys and Questionnaires; D015534:Trans-Activators / Q000276:immunology*; D014157:Transcription Factors
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000974:Antibodies, Antinuclear; D001323:Autoantibodies; C504649:PSIP1 protein, human; D015534:Trans-Activators; D014157:Transcription Factors